AWA
CADL icon

Arete Wealth Advisors’s Candel Therapeutics CADL Stock Holding History

Arete Wealth Advisors’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.98M Buy
+289,663
New +$2.19M 0.1% 184

Other funds holding CADL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $617M AUM 69.99% 1-Year Est. Return
TWM
Tanager Wealth Management Goring On Thames, United Kingdom $1.15B AUM 19.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
TGIA
Torrey Growth & Income Advisors Del Mar, California $294M AUM 37.95% 1-Year Est. Return

Arete Wealth Advisors's CADL Position: Q2 2026 in Review

Arete Wealth Advisors opened a new position in Candel Therapeutics (CADL) in Q2 2026: 289,663 shares worth $2.98M. The stake represents 0.1% of the portfolio and ranks #184 among its holdings.

61 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Arete Wealth Advisors held 289,663 shares of Candel Therapeutics worth $2.98M as of Q2 2026.
  • Candel Therapeutics was a new Arete Wealth Advisors position in Q2 2026.
  • Candel Therapeutics made up 0.1% of Arete Wealth Advisors's portfolio in Q2 2026, its #184 holding.
  • 61 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Arete Wealth Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.